Last reviewed · How we verify
oxytocin and misoprostol
At a glance
| Generic name | oxytocin and misoprostol |
|---|---|
| Also known as | oxy&miso |
| Sponsor | Jhpiego |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Combined Use of Oxytocin and Misoprostol in the Prevention of Post Partum Haemorrhage (PHASE4)
- Cooling the Uterus in C-section After Dysfunctional Labor (NA)
- Carbetocin vs Misoprostol for Postpartum Hemorrhage Prevention (NA)
- Oxytocin vs Prostaglandins for Labor Induction of Women With an Unfavorable Cervix After 24h of Cervical Ripening (PHASE3)
- Rectal Misoprostol for Reducing Blood Loss in Elective Cesarean Section (NA)
- PROMMO Trial: Oral Misoprostol vs IV Oxytocin (EARLY_PHASE1)
- Tranexamic Acid Versus Sublingual Misoprostol in Reducing Blood Loss During Elective CS in High Risk Cases (PHASE2)
- Comparison of the Efficacy of Misoprostol and Tranexamic Acid for Postpartum Hemorrhage Prophylaxis in Cesarean Delivery
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- oxytocin and misoprostol CI brief — competitive landscape report
- oxytocin and misoprostol updates RSS · CI watch RSS
- Jhpiego portfolio CI